UCB (OTCMKTS:UCBJF) Sees Unusually-High Trading Volume – What’s Next?

UCB SA (OTCMKTS:UCBJF) saw strong trading volume on Friday . 4,137 shares changed hands during trading, an increase of 446% from the previous session’s volume of 757 shares.The stock last traded at $285.29 and had previously closed at $281.55.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Wolfe Research assumed coverage on UCB in a research report on Monday, February 23rd. They set an “outperform” rating on the stock. The Goldman Sachs Group reaffirmed a “buy” rating on shares of UCB in a research report on Monday, February 16th. Six research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, UCB presently has an average rating of “Buy”.

UCB Stock Performance

The business has a fifty day moving average of $296.37 and a 200-day moving average of $295.54. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.78 and a current ratio of 1.19.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.